Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart

Clinical Science

Volumn 117, Issue 4, 2009, Pages 157-164

  Vianello, Annamaria ^a   Caponi, Laura ^b   Franzoni, Ferdinando ^a   Galetta, Fabio ^a   Rossi, Marco ^a   Taddei, Marco ^a   Malvaldi, Gino ^b   Pietrini, Pietro ^b   Santoro, Gino ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Athlete's heart; Left ventricular remodelling; Matrix metalloproteinase (MMP); Sports medicine; Tissue inhibitor of MMPs (TIMP)

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADAPTATION; ADULT; ARTICLE; ATHLETE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPORTS MEDICINE;

BIOLOGICAL MARKERS; CARDIOMEGALY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SPORTS; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 70349387977     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080278     Document Type: Article

References (26)

1. Pluim, B. M., Zwinderman, A. H., van der Laarse, A. and van der Wall, E. E. (2000) The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 101, 336-344
2. Dickhuth, H. H., Röcker, K., Mayer, F., König, D. and Korsten-Reck, U. (2004) Endurance training and cardial adaptation (athlete's heart). Herz 29, 373-380
3. Maron, B. J. and Pelliccia, A. (2006) The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 114, 1633-1644
4. Pelliccia, A., Di Paolo, F. M., Quattrini, F. M., Basso, C., Culasso, F., Popoli, G., De Luca, R., Spataro, A., Biffi, A., Thiene, G. and Maron, B. J. (2008) Outcome in athletes with marked ECG repolarization abnormalities. N. Engl. J. Med. 358, 152-161
5. McMullen, J. R. and Jennings, G. L. (2007) Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 34, 255-262
6. Altieri, P., Brunelli, C., Garibaldi, S., Nicolino, A., Ubaldi, S., Spallarossa, P., Olivotti, L., Rossettin, P., Barsotti, A. and Ghigliotti, G. (2003) Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur. J. Clin. Invest. 33, 648-656
7. D'Armiento, J. (2002) Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc. Med. 12, 97-101
8. Spinale, F. G. (2002) Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ. Res. 90, 520-530
9. Nagase, H., Visse, R. and Murphy, G. (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573
10. Pelliccia, A., Maron, B. J., De Luca, R., Di Paolo, F. M., Spataro, A. and Culasso, F. (2002) Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 105, 944-949
11. Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I. and Reichek, N. (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57, 450-458
12. Ahmed, S. H., Clark, L. L., Pennington, W. R., Webb, C. S., Bonnema, D. D., Leonardi, A. H., McClure, C. D., Spinale, F. G. and Zile, M. R. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113, 2089-2096
13. Bergman, M. R., Teerlink, J. R., Mahimkar, R., Li, L., Zhu, B. Q., Nguyen, A., Dahi, S., Karliner, J. S. and Lovett, D. H. (2007) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H1847-H1860
14. Bassiouny, H. S., Song, R. H., Hong, X. F., Singh, A., Kocharyan, H. and Glagov, S. (1998) Flow regulation of 72-kD collagenase IV (MMP2) after experimental arterial injury. Circulation 98, 157-163
15. Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F. and Tiret, L. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107, 1579-1585
16. Robertson, L., Grip, L., Mattsson Hulten, L., Hulthe, J. and Wiklund, O. (2007) Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention. J. Int. Med. 262, 659-667
17. Niessner, A., Richter, B., Penka, M., Steiner, S., Strasser, B., Ziegler, S., Heeb-Elze, E., Zorn, G., Leitner-Heinschink, A., Niessner, C. et al. (2006) Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? Atherosclerosis 186, 160-165
18. Evans, J., Powell, J. T., Schwalbe, E., Loftus, I. M. and Thompson, M. M. (2007) Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur. J. Vasc. Endovasc. Surg. 34, 302-303
19. Stintzing, S., Heuschmann, P., Barbera, L., Ocker, M., Jung, A., Kirchner, T. and Neureiter, D. (2005) Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae inflammation and apoptosis. Ann. Vasc. Surg. 19, 310-319
20. Gullestad, L., Oie, E., Ueland, T., Yndestad, A. and Aukrust, P. (2007) The role of statins in heart failure. Fund. Clin. Pharmacol. 21 (Suppl. 2), 35-40
21. Spinale, F. G. (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285-1342
22. Saenz, A. J., Lee-Lewandrowski, E., Wood, M. J., Neilan, T. G., Siegel, A. J., Januzzi, J. L. and Lewandrowski, K. B. (2006) Measurement of a plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston Marathon. Am. J. Clin. Pathol. 126, 185-189
23. Yan, A. T., Yan, R. T., Spinale, F. G., Afzal, R., Gunasinghe, H. R., Arnold, M., Demers, C., McKelvie, R. S. and Liu, P. P. (2006) Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J. Card. Failure 12, 514-519
24. Tayebjee, M. H., Nadar, S. K., MacFadyen, R. J. and Lip, G. Y. (2004) Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am. J. Hypertens. 17, 770-774
25. Masson, S., Latini, R., Anand, I. S., Barlera, S., Angelici, L., Vago, T., Tognoni, G. and Cohn, J. N. (2008) Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J. Am. Coll. Cardiol. 12, 997-1003
26. Lee, D. S., Evans, J. C., Robins, S. J.,Wilson, P.W., Albano, I., Fox, C. S., Wang, T. J., Benjamin, E. J., D'Agostino, R. B. and Vasan, R. S. (2007) γ-Glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27, 127-133